Issue Date: May 15, 2017
Sanofi to keep Cepia contract business
The French drugmaker Sanofi says it has decided not to divest Cepia, its contract manufacturing arm. The business produces active pharmaceutical ingredients at 16 Sanofi chemical and biotech sites. It also offers process development services. In the biotech field alone, the business counts more than 280 customers in 62 countries. The decision to keep Cepia is based on its financial improvement and promising prospects, Sanofi says.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society